130 related articles for article (PubMed ID: 30985000)
1. Successful direct-acting antiviral therapy in HIV/HCV co-infected patients fails to restore circulating mucosal-associated invariant T cells.
Cannizzo ES; Cerrone M; Merlini E; van Wilgenburg B; Swadling L; Ancona G; De Bona A; d'Arminio Monforte A; Klenerman P; Marchetti G
Eur J Immunol; 2019 Jul; 49(7):1127-1129. PubMed ID: 30985000
[No Abstract] [Full Text] [Related]
2. Frequencies of Circulating MAIT Cells Are Diminished in Chronic HCV, HIV and HCV/HIV Co-Infection and Do Not Recover during Therapy.
Spaan M; Hullegie SJ; Beudeker BJ; Kreefft K; van Oord GW; Groothuismink ZM; van Tilborg M; Rijnders B; de Knegt RJ; Claassen MA; Boonstra A
PLoS One; 2016; 11(7):e0159243. PubMed ID: 27416100
[TBL] [Abstract][Full Text] [Related]
3. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy.
Potter M; Odueyungbo A; Yang H; Saeed S; Klein MB;
AIDS; 2010 Jul; 24(12):1857-65. PubMed ID: 20479633
[TBL] [Abstract][Full Text] [Related]
4. Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.
Mandorfer M; Neukam K; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Ernst D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M; Reiberger T
Antivir Ther; 2014; 19(4):407-14. PubMed ID: 24342953
[TBL] [Abstract][Full Text] [Related]
5. Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.
Sherman KE; Guedj J; Shata MT; Blackard JT; Rouster SD; Castro M; Feinberg J; Sterling RK; Goodman Z; Aronow BJ; Perelson AS
Sci Transl Med; 2014 Jul; 6(246):246ra98. PubMed ID: 25101888
[TBL] [Abstract][Full Text] [Related]
6. Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.
BenMarzouk-Hidalgo OJ; Torres-Cornejo A; Gutierrez-Valencia A; Ruiz-Valderas R; Viciana P; López-Cortés LF
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):6-11. PubMed ID: 26414169
[TBL] [Abstract][Full Text] [Related]
7. Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection.
Khlaiphuengsin A; Chuaypen N; Sodsai P; Reantragoon R; Han WM; Avihingsanon A; Tangkijvanich P
PLoS One; 2020; 15(12):e0244112. PubMed ID: 33382729
[TBL] [Abstract][Full Text] [Related]
8. HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.
Papasavvas E; Azzoni L; Yin X; Liu Q; Joseph J; Mackiewicz A; Ross B; Lynn KM; Jacobson JM; Mounzer K; Kostman JR; Montaner LJ
J Viral Hepat; 2017 Oct; 24(10):865-876. PubMed ID: 28419653
[TBL] [Abstract][Full Text] [Related]
9. Mucosal-associated invariant T-cell frequency and function in blood and liver of HCV mono- and HCV/HIV co-infected patients with advanced fibrosis.
Beudeker BJB; van Oord GW; Arends JE; Schulze Zur Wiesch J; van der Heide MS; de Knegt RJ; Verbon A; Boonstra A; Claassen MAA
Liver Int; 2018 Mar; 38(3):458-468. PubMed ID: 28792648
[TBL] [Abstract][Full Text] [Related]
10. Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
Xiao H; Chen J; Wang J; Li J; Yang F; Lu H
Medicine (Baltimore); 2019 Jul; 98(30):e16524. PubMed ID: 31348267
[TBL] [Abstract][Full Text] [Related]
11. Transient liver injury associated with the early recovery of HCV-specific T-cell responses and HCV rebound in HIV-1/HCV coinfected patients undergoing highly active antiretroviral therapy.
Kang F; Chen W; Zhang X; Nie W; Fu J; Xu X; Zhao P; Zhang X; Li W; Wang FS; Zhang Z; Zhao M
J Acquir Immune Defic Syndr; 2013 Feb; 62(2):135-42. PubMed ID: 23075912
[TBL] [Abstract][Full Text] [Related]
12. Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus.
Macías J; Pineda JA; Lozano F; Corzo JE; Ramos A; León E; García-García JA; Fernández-Rivera J; Mira JA; Gómez-Mateos J
Eur J Clin Microbiol Infect Dis; 2003 Nov; 22(11):675-80. PubMed ID: 14574616
[TBL] [Abstract][Full Text] [Related]
13. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
[TBL] [Abstract][Full Text] [Related]
14. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
Grottenthaler JM; Werner CR; Steurer M; Spengler U; Berg T; Engelmann C; Wedemeyer H; von Hahn T; Stremmel W; Pathil A; Seybold U; Schott E; Blessin U; Sarrazin C; Welker MW; Harrer E; Scholten S; Hinterleitner C; Lauer UM; Malek NP; Berg CP
PLoS One; 2018; 13(6):e0197544. PubMed ID: 29874250
[TBL] [Abstract][Full Text] [Related]
15. Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy.
Majekodunmi AO; Thorne C; Malyuta R; Volokha A; Callard RE; Klein NJ; Lewis J;
Pediatr Infect Dis J; 2017 May; 36(5):e123-e129. PubMed ID: 28403051
[TBL] [Abstract][Full Text] [Related]
16. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Clin Trials; 2018 Dec; 19(6):225-234. PubMed ID: 30890063
[TBL] [Abstract][Full Text] [Related]
17. Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.
Isakov V; Gankina N; Morozov V; Kersey K; Lu S; Osinusi A; Svarovskaia E; Brainard DM; Salupere R; Orlova-Morozova E; Zhdanov K
Clin Drug Investig; 2018 Mar; 38(3):239-247. PubMed ID: 29177645
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the treatment of HIV/HBV and HIV/HCV co-infection.
Masgala A; Bonovas S; Nikolopoulos GK
Mini Rev Med Chem; 2012 Aug; 12(9):890-904. PubMed ID: 22530578
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
[TBL] [Abstract][Full Text] [Related]
20. Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy.
Lee S; Saraswati H; Yunihastuti E; Gani R; Price P
Clin Immunol; 2014 Dec; 155(2):149-59. PubMed ID: 25283333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
